Literature DB >> 8978843

Indole inhibitors of human nonpancreatic secretory phospholipase A2. 2. Indole-3-acetamides with additional functionality.

R D Dillard1, N J Bach, S E Draheim, D R Berry, D G Carlson, N Y Chirgadze, D K Clawson, L W Hartley, L M Johnson, N D Jones, E R McKinney, E D Mihelich, J L Olkowski, R W Schevitz, A C Smith, D W Snyder, C D Sommers, J P Wery.   

Abstract

As reported in our previous paper, a series of indole-3-acetamides which possessed potency and selectivity as inhibitors of human nonpancreatic secretory phospholipase A2(hnps-PLA2) was developed. The design of these compounds was based on information derived from x-ray crystal structures determined for complexes between the enzyme and its inhibitors. We describe here the further implementation of this structure-based design strategy and continued SAR development to produce indole-3-acetamides with additional functionalities which provide increased interaction with important residues within the enzyme active site. These efforts led to inhibitors with substantially enhanced potency and selectivity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8978843     DOI: 10.1021/jm960486n

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

Review 1.  Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention.

Authors:  Edward A Dennis; Jian Cao; Yuan-Hao Hsu; Victoria Magrioti; George Kokotos
Journal:  Chem Rev       Date:  2011-09-12       Impact factor: 60.622

2.  The first potent inhibitor of mammalian group X secreted phospholipase A2: elucidation of sites for enhanced binding.

Authors:  Brian P Smart; Rob C Oslund; Laura A Walsh; Michael H Gelb
Journal:  J Med Chem       Date:  2006-05-18       Impact factor: 7.446

3.  Design of 1-arylsulfamido-2-alkylpiperazine derivatives as secreted PLA2 inhibitors.

Authors:  Preethi Badrinarayan; P Srivani; G Narahari Sastry
Journal:  J Mol Model       Date:  2010-06-23       Impact factor: 1.810

4.  Predicting target-ligand interactions with graph convolutional networks for interpretable pharmaceutical discovery.

Authors:  Paola Ruiz Puentes; Laura Rueda-Gensini; Natalia Valderrama; Isabela Hernández; Cristina González; Laura Daza; Carolina Muñoz-Camargo; Juan C Cruz; Pablo Arbeláez
Journal:  Sci Rep       Date:  2022-05-19       Impact factor: 4.996

5.  Discovery of a Series of Indole-2 Carboxamides as Selective Secreted Phospholipase A2 Type X (sPLA2-X) Inhibitors.

Authors:  Laurent Knerr; Fabrizio Giordanetto; Peter Nordberg; Daniel Pettersen; Nidhal Selmi; Hans-Georg Beisel; Hannah de la Motte; Thomas Olsson; Tim D J Perkins; Margareta Herslöf; Åsa Månsson; Mikael Dahlström; Ingemar Starke; Johan Broddefalk; Gabrielle Saarinen; Fredrik Klingegård; Eva Hurt-Camejo; Birgitta Rosengren; Johan Brengdahl; Frank Jansen; Mattias Rohman; Jenny Sandmark; Kenth Hallberg; Tomas Åkerud; Robert G Roth; Marie Ahlqvist
Journal:  ACS Med Chem Lett       Date:  2018-06-23       Impact factor: 4.345

6.  Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2.

Authors:  Rob C Oslund; Nathan Cermak; Michael H Gelb
Journal:  J Med Chem       Date:  2008-07-08       Impact factor: 7.446

Review 7.  pCRP-mCRP Dissociation Mechanisms as Potential Targets for the Development of Small-Molecule Anti-Inflammatory Chemotherapeutics.

Authors:  Vittorio Caprio; Lina Badimon; Mario Di Napoli; Wen-Hui Fang; Glenn R Ferris; Baoqiang Guo; Rocco S Iemma; Donghui Liu; Yasmin Zeinolabediny; Mark Slevin
Journal:  Front Immunol       Date:  2018-05-28       Impact factor: 7.561

Review 8.  Structural and Functional Aspects of Targeting the Secreted Human Group IIA Phospholipase A2.

Authors:  Ryung Rae Kim; Zheng Chen; Timothy J Mann; Karine Bastard; Kieran F Scott; W Bret Church
Journal:  Molecules       Date:  2020-09-28       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.